Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk

Summary

This study will evaluate the Heartfelt device, a novel, passive monitoring system that detects early signs of fluid build-up in patients (oedema) with heart failure by measuring changes in foot and lower leg volume through capture of 3D images. The trial will assess whether this device, when added to standard NHS care, improves quality of life and reduces heart failure-related events compared to standard care alone.

Eligibility

Inclusion Criteria:

* Adults \>18 years
* Diagnosis of heart failure (any aetiology or left ventricular ejection fraction classification), any timeframe
* Currently prescribed ≥40 mg/day of furosemide (or equivalent loop diuretic) for at least one month.
* Heart failure hospital admission and moderate or severe leg oedema in the previous 12 months.
* Lives in the UK, with a home environment suitable for installation of the Heartfelt device.

Exclusion Criteria:

* Amputation of both feet
* Bed-bound for more than 20h per 24h period
* Bandages to lower limbs every day
* Regular wheelchair user inside their home
* No fixed abode
* Participation in another interventional trial that may interfere with endpoints
* Life expectancy \<6 months, in the opinion of the investigator
* Inability to provide informed consent due to cognitive impairment
* Language barriers that preclude understanding of trial procedures (unless translation resources are available in relevant language)
* Inability to install the device (even with assistance) allowing at least 6 months of data capture by the end of the study.
* Patients with severe aortic stenosis or awaiting a heart procedure or surgery
* Patient with end stage renal disease (eGFR \<20)
* Pregnancy or lack of contraceptive measures if of child-bearing potential

Conditions2

Browse More Trials